Chinese Journal of Dermatology ›› 2024, e20220644.doi: 10.35541/cjd.20220644
• Reviews • Previous Articles Next Articles
Yao Manxue, Zhou Naihui
Received:
2022-09-07
Revised:
2023-06-20
Online:
2024-01-29
Published:
2024-05-08
Contact:
Zhou Naihui
E-mail:zhounaihui@163.com
Supported by:
Yao Manxue, Zhou Naihui. Stevens-Johnson syndrome/toxic epidermal necrolysis associated with programmed death-1/programmed death-ligand 1 inhibitors[J]. Chinese Journal of Dermatology,2024,e20220644. doi:10.35541/cjd.20220644
[1] | Li K, Tian H. Development of small⁃molecule immune checkpoint inhibitors of PD⁃1/PD⁃L1 as a new therapeutic strategy for tumour immunotherapy[J]. J Drug Target, 2019,27(3):244⁃256. doi: 10.1080/1061186X.2018.1440400. |
[2] | Costa F, Marchica V, Storti P, et al. PD⁃L1/PD⁃1 axis in multiple myeloma microenvironment and a possible link with CD38⁃mediated immune⁃suppression[J]. Cancers(Basel), 2021,13(2):1⁃17. doi: 10.3390/cancers13020164. |
[3] | Dasanu CA. Late⁃onset Stevens⁃Johnson syndrome due to nivolumab use for hepatocellular carcinoma[J]. J Oncol Pharm Pract, 2019,25(8):2052⁃2055. doi: 10.1177/1078155219830166. |
[4] | Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer(SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017,5(1):95. doi: 10.1186/s40425⁃017⁃0300⁃z. |
[5] | Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor⁃related dermatologic adverse events[J]. J Am Acad Dermatol, 2020,83(5):1255⁃1268. doi: 10.1016/j.jaad.2020.03.132. |
[6] | National Cancer Institute. Common terminology criteria for adverse events(CTCAE v5.0)[DB/OL].(2017⁃11⁃27)[2023⁃08⁃08]. https://ctep.cancer.gov/protocolDevelopment/electronic_ applications/ctc.html. |
[7] | Oguri T, Sasada S, Shimizu S, et al. A case of Guillain⁃Barré syndrome and Stevens⁃Johnson syndrome/toxic epidermal necrosis overlap after pembrolizumab treatment[J]. J Investig Med High Impact Case Rep, 2021,9:232470962 11037462. doi: 10.1177/23247096211037462. |
[8] | Alexandris D, Alevizopoulos N, Gakiopoulou H, et al. Cutaneous Stevens Johnson⁃toxic epidermal necrolysis immunotherapy related toxicities in lung cancer patients[J]. J Oncol Pharm Pract, 2022,28(5):1276⁃1282. doi: 10.1177/10781552221074623. |
[9] | Keerty D, Koverzhenko V, Belinc D, et al. Immune⁃mediated toxic epidermal necrolysis[J]. Cureus, 2020,12(8):e9587. doi: 10.7759/cureus.9587. |
[10] | Kian W, Zemel M, Elobra F, et al. Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis[J]. Anticancer Drugs,2022,33(1):e738⁃e740. doi:10.1097/CAD.0000000000001162. |
[11] | Basu P, Tong Y, Hinds BR, et al. Nivolumab⁃induced toxic epidermal necrolysis with retiform purpura[J]. Br J Dermatol, 2020,183(2):e32. doi: 10.1111/bjd.19031. |
[12] | Gracia⁃Cazaña T, Padgett E, Calderero V, et al. Nivolumab⁃associated Stevens⁃Johnson syndrome in a patient with lung cancer[J]. Dermatol Online J, 2021,27(3):13. doi: 10.5070/D3273052777. |
[13] | Zhang J, Zhang P, Xu Q Y, et al. Pembrolizumab associated Stevens⁃Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma[J]. Australas J Dermatol, 2022,63(1):e71⁃e74. doi:10.1111/ajd.13704. |
[14] | Gallo Marin B, Oliva R, Kahn B, et al. Pembrolizumab⁃induced toxic epidermal necrolysis in a patient with metastatic esophageal adenocarcinoma[J]. R I Med J(2013), 2022,105(3):34⁃36. |
[15] | Saw S, Lee HY, Ng QS. Pembrolizumab⁃induced Stevens⁃Johnson syndrome in non⁃melanoma patients[J]. Eur J Cancer, 2017,81:237⁃239. doi: 10.1016/j.ejca.2017.03.026. |
[16] | Robinson S, Saleh J, Curry J, et al. Pembrolizumab⁃induced Stevens⁃Johnson syndrome/toxic epidermal necrolysis in a patient with metastatic cervical squamous cell carcinoma: a case report[J]. Am J Dermatopathol, 2020,42(4):292⁃296. doi: 10. 1097/DAD.0000000000001527. |
[17] | Chow K, O′Leary C, Paxton⁃Hall F, et al. Pembrolizumab⁃induced toxic epidermal necrolysis: case report[J]. Oxf Med Case Reports, 2022,2022(3):omac025. doi: 10.1093/omcr/omac025. |
[18] | Salati M, Pifferi M, Baldessari C, et al. Stevens⁃Johnson syndrome during nivolumab treatment of NSCLC[J]. Ann Oncol, 2018,29(1):283⁃284. doi: 10.1093/annonc/mdx640. |
[19] | Haratake N, Tagawa T, Hirai F, et al. Stevens⁃Johnson syndrome induced by pembrolizumab in a lung cancer patient[J]. J Thorac Oncol, 2018,13(11):1798⁃1799. doi: 10.1016/j.jtho.2018.05.031. |
[20] | Hwang A, Iskandar A, Dasanu CA. Stevens⁃Johnson syndrome manifesting late in the course of pembrolizumab therapy[J]. J Oncol Pharm Pract, 2019,25(6):1520⁃1522. doi: 10.1177/1078 155218791314. |
[21] | Watanabe Y, Yamaguchi Y, Takamura N, et al. Toxic epidermal necrolysis accompanied by several immune⁃related adverse events developed after discontinuation of nivolumab[J]. Eur J Cancer, 2020,131:1⁃4. doi: 10.1016/j.ejca.2020.02.044. |
[22] | Cai ZR, Lecours J, Adam JP, et al. Toxic epidermal necrolysis associated with pembrolizumab[J]. J Oncol Pharm Pract, 2020,26(5):1259⁃1265. doi: 10.1177/1078155219890659. |
[23] | Koshizuka K, Sakurai D, Sunagane M, et al. Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer[J]. Clin Case Rep, 2021,9(2):848⁃852. doi: 10. 1002/ccr3.3695. |
[24] | Peng Y, Yu Q, Zhang X, et al. Toxic epidermal necrolysis during camrelizumab treatment for esophageal squamous cell carcinoma[J]. Contact Dermatitis, 2022,86(5):417⁃419. doi: 10.1111/cod. 14038. |
[25] | Griffin LL, Cove⁃Smith L, Alachkar H, et al. Toxic epidermal necrolysis(TEN) associated with the use of nivolumab(PD⁃1 inhibitor) for lymphoma[J]. JAAD Case Rep, 2018,4(3):229⁃231. doi: 10.1016/j.jdcr.2017.09.028. |
[26] | Zhao Y, Cao Y, Wang X, et al. Treatment of PD⁃1 inhibitor⁃associated toxic epidermal necrolysis: a case report and brief review[J]. Onco Targets Ther, 2022,15:345⁃351. doi: 10.2147/OTT.S353743. |
[27] | Yang H, Ma Q, Sun Y, et al. Case report: toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma[J]. Front Oncol, 2022,12:1065137. doi: 10. 3389/fonc.2022.1065137. |
[28] | Borg L, Buhagiar M, La Ferla E, et al. Pembrolizumab⁃induced toxic epidermal necrolysis[J]. Case Rep Oncol, 2022,15(3):887⁃893. doi: 10.1159/000526931. |
[29] | Saad E, Adhikari P, Antala D, et al. Steven⁃Johnson syndrome: a rare but serious adverse event of nivolumab use in a patient with metastatic gastric adenocarcinoma[J]. J Med Cases, 2022,13(9):449⁃455. doi: 10.14740/jmc3992. |
[30] | Huang Y, Zhu L, Ma X, et al. A case of sintilimab⁃induced SJS/TEN: dermatologic adverse reactions associated with programmed cell death protein⁃1 inhibitors[J]. Dermatol Ther, 2022,35(9):e15663. doi: 10.1111/dth.15663. |
[31] | Wu JY, Kang K, Yi J, et al. Pembrolizumab⁃induced Stevens⁃Johnson syndrome in advanced squamous cell carcinoma of the lung: a case report and review of literature[J]. World J Clin Cases, 2022,10(18):6110⁃6118. doi: 10.12998/wjcc.v10.i18.6110. |
[32] | Li G, Gong S, Wang N, et al. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non⁃small cell lung cancer and comorbid pulmonary tuberculosis: a case report[J]. Front Immunol, 2022,13:989966. doi: 10.3389/fimmu.2022.989966. |
[33] | 李腊梅, 张思平. PD⁃1抑制剂致中毒性表皮坏死松解症2例并文献复习[J].中国皮肤性病学杂志, 2022,36(7):815⁃818. doi:10.13735/j.cjdv.1001⁃7089.202109096. |
[34] | 马慧淼, 陈媚, 刘猛, 等. 纳武单抗导致Stevens⁃Johnson综合征1例[J]. 中国肿瘤临床, 2020,47(2):105⁃106. doi: 10.3969/j.issn.1000⁃8179.2020.02.449. |
[35] | 贺旭, 吕聪聪, 毕新岭. 帕博利珠单抗引起中毒性表皮坏死松解症一例[J]. 实用皮肤病学杂志, 2021,14(5):309⁃311. doi:10.11786/sypfbxzz.1674⁃1293.20210514. |
[36] | 范秀丛, 白荣, 李语玲, 等. 帕博利珠单抗致致死性Stevens⁃Johnson综合征/中毒性表皮坏死松解症1例[J]. 中国医院药学杂志, 2021,41(12):1281⁃1282. doi: 10.13286/j.1001⁃5213. 2021.12.21. |
[37] | 邓爱清, 殷晓芹, 朱秋燕, 等. 替雷利珠单抗相关中毒性表皮坏死松解症1例[J]. 中国医院药学杂志, 2021,41(19):2039⁃2040. doi: 10.13286/j.1001⁃5213.2021.19.22. |
[38] | 程明霞, 陈叶珊, 赵迎超, 等. 替雷利珠单抗致中毒性表皮坏死松解型药疹1例[J]. 医药导报, 2022,41(4):581⁃583. doi:10.3870/j.issn.1004⁃0781.2022.04.027. |
[39] | 单彬, 吕雅蕾, 侯娟, 等. 信迪利单抗致中毒性表皮坏死松解症1例[J]. 医药导报, 2022,41(2):263⁃265. doi: 10.3870/j.issn.1004⁃0781.2022.02.027. |
[40] | 胡紫馨, 董慧静, 李承旭, 等. 免疫检查点抑制剂相关Stevens⁃Johnson综合征一例[J]. 中国麻风皮肤病杂志, 2023,39(1):31⁃34. doi: 10.12144/zgmfskin202301031. |
[41] | 郭虹霞, 常慧玲, 冯慧晶. 免疫相关中毒性表皮坏死松解症一例及文献复习[J]. 中国肿瘤生物治疗杂志, 2022,29(11):1006⁃1009. doi: 10.3872/j.issn.1007⁃385x.2022.11.008. |
[42] | 张丽, 赵冰清, 张艳华. 特瑞普利单抗致中毒性表皮坏死松解症1例[J]. 实用药物与临床, 2022,25(7):643⁃645. doi: 10. 14053/j.cnki.ppcr.202207016. |
[43] | Saito Y, Abe R. New insights into the diagnosis and management of Stevens⁃Johnson syndrome and toxic epidermal necrolysis[J]. Curr Opin Allergy Clin Immunol, 2023,23(4):271⁃278. doi: 10. 1097/ACI.0000000000000914. |
[44] | 丁心静, 丁江华. 皮肤免疫相关不良事件与PD⁃1/PD⁃L1抑制剂临床疗效相关性的研究进展[J]. 国际肿瘤学杂志, 2022,49(4):225⁃228. doi: 10.3760/cma.j.cn371439⁃20210604⁃0040. |
[45] | Maloney NJ, Ravi V, Cheng K, et al. Stevens⁃Johnson syndrome and toxic epidermal necrolysis⁃like reactions to checkpoint inhibitors: a systematic review[J]. Int J Dermatol, 2020,59(6):e183⁃e188. doi: 10.1111/ijd.14811. |
[46] | Yang L, Shou YH, Li F, et al. Retrospective study of 213 cases of Stevens⁃Johnson syndrome and toxic epidermal necrolysis from China[J]. Burns, 2020,46(4):959⁃969. doi: 10.1016/j.burns. 2019.10.008. |
[47] | 刘敏, 李忠东. 实例探讨药物引起SJS或TEN的评分方法——Naranjo评分与ALDEN评分比较[J]. 中国药物应用与监测, 2014,11(4):247⁃249. |
[48] | 中华医学会皮肤性病学分会药物不良反应研究中心. Stevens⁃Johnson综合征/中毒性表皮坏死松解症诊疗专家共识[J]. 中华皮肤科杂志, 2021,54(5):376⁃381. doi: 10.35541/cjd.2020 1177. |
[49] | Tsai TY, Huang IH, Chao YC, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta⁃analysis[J]. J Am Acad Dermatol, 2021,84(2):390⁃397. doi: 10.1016/j.jaad.2020.08.122. |
[50] | Shah R, Chen S T, Kroshinsky D. Use of cyclosporine for the treatment of Stevens⁃Johnson syndrome/toxic epidermal necrolysis[J]. J Am Acad Dermatol,2021,85(2):512⁃513. doi:10.1016/j.jaad.2018.09.063. |
[51] | Zhang S, Tang S, Li S, et al. Biologic TNF⁃alpha inhibitors in the treatment of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a systemic review[J]. J Dermatolog Treat, 2020,31(1):66⁃73. doi: 10.1080/09546634.2019.1577548. |
[52] | Hasegawa A, Abe R. Recent advances in managing and understanding Stevens⁃Johnson syndrome and toxic epidermal necrolysis[J]. F1000Res, 2020,9. doi: 10.12688/f1000research. 24748.1. |
[53] | Creamer D, Walsh S A, Dziewulski P, et al. UK guidelines for the management of Stevens⁃Johnson syndrome/toxic epidermal necrolysis in adults 2016[J]. J Plast Reconstr Aesthet Surg, 2016,69(6):e119⁃e153. doi:10.1016/j.bjps.2016.01.034. |
[1] | Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52. |
[2] | Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs [J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75. |
[3] | Chen Jiaqi, Zhang Jin, Tang Jun. Relationships between coronavirus disease 2019 and psoriasis [J]. Chinese Journal of Dermatology, 2025, 58(1): 84-88. |
[4] | Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829. |
[5] | Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742. |
[6] | Cheng Ruixuan, Zhang Chunlan, Duan Dawei, Zang Dandan, Du Xin, Wang Feng. Expression levels of complement regulatory proteins CD55 and CD59 in the peripheral blood of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2024, 57(8): 715-720. |
[7] | Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy [J]. Chinese Journal of Dermatology, 2024, 57(6): 570-574. |
[8] | Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482. |
[9] | Guo Lan, Jin Hongzhong. Small-molecule/biological agents in the treatment of pruritus [J]. Chinese Journal of Dermatology, 2024, 57(5): 475-478. |
[10] | Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230429-e20230429. |
[11] | Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358. |
[12] | Zhou Tiantian, Wu Xuege, Yang Huan, Fang Xiao, Jiang Jinqiu, Chen Jingsi, Luo Xiaoyan, Wang Hua. Analysis of the etiology and factors associated with the severity of chronic spontaneous urticaria in children [J]. Chinese Journal of Dermatology, 2024, 57(4): 324-330. |
[13] | Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378. |
[14] | Yao Wo, Wang Huiying. Lanadelumab in the treatment of hereditary angioedema: a systematic review of clinical trials [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230378-e20230378. |
[15] | Zhang Yude, Wang Hongjuan, Kang Xiaojing. Stem cell therapy for vitiligo: advances in basic and clinical research [J]. Chinese Journal of Dermatology, 2024, 0(3): 20240127-e20240127. |
|